Home » Newsletters » BioWorld Science

BioWorld Science

June 10, 2004

View Archived Issues

Montelukast protects gastric mucosa against the adverse effects of alendronate

CDP-870 improves quality of life of Crohn's disease patients

Glucose-lowering effects of NHE-1 inhibitor CP-642353

OSI Pharmaceuticals updates second quarter progress

Glycogen synthase kinase 3 inhibitors function as insulin mimetics in vitro

Effect of peptide PYY on exocrine pancreatic function and gallbladder emptying

CuraGen and TopoTarget collaborate on novel HDAC inhibitor

Genelabs to withdraw Anastar MAA with resubmission planned

New phase III study of CellCept for myasthenia gravis

Celmed BioSciences to acquire NewBiotics

FDA lifts clinical hold on DX-88 trials

Pivotal phase II/III trial of MBP-8298 cleared by Health Canada

Studies report on the safety and efficacy of sodium oxybate in treating narcolepsy-cataplexy

Approval for new Arixtra indications

European approval sought for MS-325

Phase II plans for Oxycyte

Cubicin European MAA planned by year-end 2004

Chemokine receptor agonist CRIC-3 developed for allergic diseases

Niflumic acid, MSI-2216 block mucus expression in vitro

Antitumor effects found with AP-12009 in recurrent high-grade gliomas

ARH-460-16-2 binds to an antigen expressed in several human tumor types

New PPARalpha agonists prepared and tested at Janssen

Novel PPARdelta modulators described by researchers at Servier

Glenmark scientists present novel PDE4 inhibitors

New anti-HCV agents targeting IRES-mediated translation claimed by Isis

Two series of histamine H3 receptor modulators and their use reported by Janssen

Chugai scientists describe new benzofuran-based FTase inhibitors

Novel DPP-IV inhibitors in early development at Merck

Two series of PPARdelta agonists and their use patented by Novo Nordisk

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...